Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Intervention Indication Therapeutic Area Year Actions
Pembrolizumab-vibostolimab with etoposide and platinum chemotherapy for previously untreated extensive-stage small cell lung cancer Etoposide , Pembrolizumab-vibostolimab (MK-7684; MK7684A; Vibostolimab) , Platinum-based chemotherapy Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2023 View  |  Download
Pemigatinib for locally advanced or metastatic, relapsed or refractory cholangiocarcinoma with FGFR2 fusion or rearrangement Pemigatinib (INCB054828) Cholangiocarcinoma Gastrointestinal Cancer 2019 View  |  Download
Pemigatinib for treating myeloproliferative neoplasms with FGFR1 rearrangement Pemigatinib (INCB054828) Myeloproliferative Neoplasms Haematological Cancer and Lymphomas 2022 View  |  Download
Pentetrazol for Idiopathic Hypersomnia and Narcolepsy Type 2 Pentetrazol (BTD-001) Hypersomnia , Narcolepsy Neurology 2018 View  |  Download
Pentosan polysulfate sodium (Elmiron) for bladder pain syndrome (interstitial cystitis) Pentosan polysulphate sodium (Elmiron; AK-150) Bladder pain syndrome , Interstitial cystitis , Painful bladder syndrome Nephrology , Urology 2017 View  |  Download
Perampanel (Fycompa) for Paediatric Epilepsy Perampanel (Fycompa; E 2007; ER-155055-90) Epilepsy Neurology 2018 View  |  Download
Pertuzumab and trastuzumab (fixed-dose combination) in addition to chemotherapy for breast cancer Pertuzumab and Trastuzumab (Phesgo; RO7198574) (fixed dose combination: Trastuzumab; Pertuzumab) Breast cancer Breast Cancer 2019 View  |  Download
Pevonedistat in addition to azacitidine for Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low Blast Acute Myeloid Leukemia – first-line Azacitidine (Vidaza; CC-486) , Pevonedistat (MLN-4924; TAK-924) Acute myeloid leukaemia (AML) , Chronic myelomonocytic leukaemia (CMML) , Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2020 View  |  Download
Pexastimogene devacirepvec (pexa-vec) for hepatocellular carcinoma – first line Pexastimogene devacirepvec (Pexa-vec; JX-594) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2017 View  |  Download
Pexidartinib for tenosynovial giant cell tumour Pexidartinib (PLX3397) Tenosynovial giant cell tumour (TGCT) Oncology 2019 View  |  Download
1 2 81 82 83 84 85 117 118
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications